A multicentre study of tenoxicam for the treatment of osteo-arthritis and rheumatoid arthritis in general practice.
A study was undertaken to investigate the efficacy and tolerability of 20 mg/day tenoxicam given orally for 12 weeks in a general practice setting in a broad range of patients suffering from osteo-arthritis or rheumatoid arthritis. The group of 2963 patients was recruited from 252 general practices. Some patients (60%) continued treatment into the long-term phase of the trial, beyond 12 weeks, whereas other patients (31%) elected to continue treatment beyond 52 weeks. There was a reduction in the number of patients recording pain and stiffness over the course of the study. Adverse events were typical of a nonsteroidal anti-inflammatory drug with no unexpected or unusual side-effects. It is concluded that tenoxicam can be recommended for use in osteo-arthritis and rheumatoid arthritis.
Langdon
C G
CG
Symons Medical Centre, Maidenhead, UK.
Moran
D G
DG
Jamieson
V
V
Spence
S
S
Hill
S A
SA
D000284:Administration, Oral; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004341:Drug Evaluation; D005194:Family Practice; D005260:Female; D006801:Humans; D008297:Male; D010003:Osteoarthritis / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy; D010894:Piroxicam / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012074:Remission Induction; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; C032801:tenoxicam